SMO and chronic myelogenous leukemia, BCR-ABL1 positive: The aptamer specifically disrupted β-arrestin 2-signaling complexes, and thus it inhibited the downstream signaling processes of both Hh/Smo and Wnt/Fz pathways; these effects finally led to impaired tumorigenic growth of CML cell line K562 and patient-derived samples.83